Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer's Disease

Next Previous
Trial Profile

Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium oligomannurarate (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Shanghai Green Valley Pharmaceutical

Most Recent Events

  • 27 Apr 2020 According to a Shanghai Green Valley Pharmaceutical media release, the NDA approval by the China NMPA, was based on the full data package of GV-971 nonclinical, clinical, chemistry, manufacturing and control (CMC), and the China Phase III clinical efficacy and safety outcomes (NCT02293915).
  • 02 Nov 2019 According to a Shanghai Green Valley Pharmaceutical media release, the Chinas National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of mild to moderate Alzheimer's disease (AD) and improving cognitive function.
  • 02 Nov 2019 According to a Shanghai Green Valley Pharmaceutical media release, this trial was led by the Mental Health Center affiliated to Shanghai Jiao Tong University School of Medicine and Peking Union Medical College Hospital.The entire clinical trial was managed by Ai Kunwei (formerly Kuntai).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top